To answer the demand for fill finish manufacturing capacity, CARBOGEN AMCIS has built a new state-of-the-art facility in St. Beauzire in France. This new facility has two manufacturing lines and can offer both liquid and lyophilized drug product forms.

To compliment the drug substance offering that CARBOGEN AMCIS has, and in line with the rise of Antibody Drug Conjugates (ADC’s) and other highly potent compounds, this new facility is capable of handling products that require the highest containment. This handling capability covers development, manufacturing and release testing, making CARBOGEN AMCIS a great partner for highly potent drug products as well as conventional compounds and biologics.

With over 40 years experience of offering CDMO services, CARBOGEN AMCIS has a good understanding of client needs. We understand that each project is unique and is handled in such a way. Our team of experts bring added value to your project with a pragmatic and knowledgeable approach. With timelines to a manufacturing slot often being very long, CARBOGEN AMCIS can accelerate your drug development pipeline with access to development and manufacturing.